Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in France / NCT06245993
Recruiting Observational

Study of Residuals Deformities After Diaphyseal Femoral Fracture in Children Treated by Skin Traction

NCT06245993 · tracked via the Priya Life Science France tracker
Sponsor
Centre Hospitalier Universitaire, Amiens
Phase
Observational
Started
2023-12-15
Last updated
2024-02-07

Condition(s) studied

EOS

Investigational drug(s) / intervention(s)

EOS imaging

EOS imaging: EOS imaging 3 years after skin traction treatment for femoral shaft fracture.

Study summary

Diaphyseal femoral fracture in children \<6 years old are treated by the skin traction technique. As demonstrated by numerous studies, given the significant potential for bone remodeling in young children, remodeling (excluding rotational disorder) allows anatomical correction. The aim of this study is to confirm, via EOS imaging, the absence of residual deformities 3 years after the end of treatment in children treated in Amiens hospital department.

Eligibility

Sex
ALL
Min age
—
Max age
6 Years
Healthy volunteers
No
Inclusion Criteria: * \<6 years old at the time of the fracture * treatment by skin zenith traction * femoral shaft fracture, traumatic, unilateral Exclusion Criteria: * Multiple fracture * pathological fracture * history of lower limb fracture * contraindication to zenith traction

Primary outcome measure(s)

  • absence of lower limb overgrowth — 3 years
    Leg Length Discrepancy in EOS imaging

Trial sites (1)

FacilityCityRegionStatus
CHU Amiens Amiens France Recruiting

More Centre Hospitalier Universitaire, Amiens trials in France

Study of the Link Between Structural Alterations in the Hypothalamus and Cardiac Dysautonomia in Drug-resistant Epilepsy Recruiting
MRI-Eye Tracking Pairing, a Tool for Assessing Social Cognition in Children With ASD Recruiting
Is Cap Assisted Endoscopy Useful in Acute Upper Gastrointestinal Bleeding ? Recruiting
Salivary Replication of BK Virus in Post-kidney Transplant Starting soon
Does Urinary TIMP2 and IGFBP7 Can Identify High Risk Patients of Progression From Mild and Moderate to Severe Acute Kidney Injury During Septic Shock? Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06245993 on ClinicalTrials.gov ↗ ← All trials in France